Table 2.
The successful treatment rates for single-agent MTX/FA chemotherapy and second- and third-line therapies grouped by FIGO score
| FIGO score | 1st line MTX/FA | Success rate % (n) |
2nd line ActD | Success rate % (n) |
2nd line EMA/ CO | Success rate % (n) |
3rd-line (EMA/CO or TE/TP) | Success rate % (n) |
|---|---|---|---|---|---|---|---|---|
| 0 | 57 | 74 (42) | 13 | 92 (12) | 2 | 100 (2) | 1 | 100 (1) |
| 1 | 91 | 78 (71) | 16 | 100 (16) | 4 | 100 (4) | ||
| 2 | 128 | 64 (82) | 34 | 94 (32) | 12 | 92 (11) | 3 | 100 (3) |
| 3 | 145 | 52(75) | 40 | 90 (36) | 30 | 90 (27) | 7 | 100 (7) |
| 4 | 120 | 44 (53) | 34 | 91 (31) | 33 | 100 (33) | 3 | 100 (3) |
| 5 | 32 | 44 (14) | 11 | 82 (9) | 7 | 86 (6) | 3 | 100 (3) |
| 6 | 31 | 32 (10) | 4 | 100 (4) | 17 | 94 (16) | 1 | 100 (1) |
| 7 | 5 | 20 (1) | 1 | 100 (1) | 3 | 100 (3) | ||
| Total | 609 | 57.2 (348) | 153 | 92.2 (141) | 108 | 94.4 (102) | 18 | 100 (18) |
ActD, actinomycin D; EMA/CO, etoposide; MTX and ActD alternating weekly with cyclophosphamide and vincristine; MTX/FA, methotrexate and folonic acid; TE/TP, paclitaxel/cisplatin alternating with paclitaxel/etoposide.